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are, what we do, 
It isn't often that one has the opportunity to 
publicly express debts of gratitude to those who have 
significantly influenced and contributed to one's ca- 
reer. I would like to mention several outstanding men 
with whom I have worked and thank them for the 
time, direction, and counsel they have generously 
given to me. In 1950 Dr. Jack Cranley, a long-time 
prominent member of this Society, identified me as a 
talented scrub technician, and through his encour- 
agement I set forth on my career path in medicine. He 
made it possible for me to attend medical school by 
providing summer and part-time employment dur- 
ing my high school, pre-medical, and medical school 
education. My educational experience was also high- 
lighted by medical innovators, Dr. A1 Star, Dr. Charles 
Dotter, Dr. A. G. Morrow, and Dr. Norman E. Shum- 
way, who provided me with direction, insight, goals, 
and opportunities, for which I am forever grateful. 
One of the prerogatives attached to the presiden- 
tial office of a major society includes the freedom to 
choose the subject matter for the presidential ddress. 
Reflection on my part resulted in the potential for two 
presentations. The one I have chosen not to give 
deserves mention. 
As physicians, we have after many years of denial 
finally come to accept hat we indeed are in a service 
business. Our customers are our patients, and our job 
is prevention, maintenance, and repair. 
This address marks the 49th Presidential Address, 
and until today none of the former presentations have 
focused on prevention. At the risk of eliminating our 
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livelihood, I thought it might be appropriate to give 
the first Presidential Address on the Prevention of 
Vascular Disease. I originally chose as my topic: The 
Therapeutic Benefit of Red Wine Drinking on the 
Cardiovascular System. Overwhelming evidence is 
now available that documents how the ravages of 
atherosclerosis can be delayed by moderate daily 
consumption of red wine. Components within the 
extract obtained from the red grape skin have a 
salubrious effect on the cardiovascular system. It has 
been documented that the extract hat is released 
from the red grape skin upon ingestion causes de- 
creased platelet adhesiveness, increased HDL level, 
decreased serum lipids, and arterial wall relaxation 
that persists well beyond the presence of a measurable 
blood alcohol evel.l,2 This extract also has a beneficial 
effect on the endothelium. These therapeutic benefits 
related to wine ingestion have collectively become 
known as "the French Paradox. ''3 Nitric oxide is 
found in high concentrations in the extract of the red 
grape and has been identified as one of the critical 
components in the resultant beneficial effect. These 
findings hould then extrapolate oproviding vascular 
surgeons with an excellent rationale for prescribing 
moderate red wine consumption for all of their 
patients. The author of this manuscript provides 
testimony that those wines bearing the Fogarty label 
are particularly beneficial in their antiatherogenic 
effect. However, despite the ever-increasing evidence 
extolling the positive health benefits of medicinal red 
wine consumption, as of this writing there is still no 
allowable reimbursement code for this type of  coun- 
sel, nor is a prescription for red wine viewed as an 
acceptable drug. In addition, the FDA most certainly 
would have concerns about "off-label use" and ap- 
propriate dosages. Despite these obstacles to the 
adoption of this treatment method, as an enologist 
and physician I am hopeful that red wine might 
someday be considered a "valued drug" by the FDA. 
However, because I feel a responsibility o depart my 
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presidential office leaving information and a perspec- 
tive that has immediate applicability, I was forced to 
abandon this topic. 
Moving beyond that lighter medical note, I would 
like to address the socioeconomic and technologic 
changes that are occurring in the field of medicine and 
specifically how these changes impact our specialty, 
It is noteworthy that of the 48 former SVS 
presidents, only two have been private practitioners in 
the traditional sense. Although my early career and 
current activity is within an academic enter, the 
major portion of my clinical experience was spent in a 
private practice nvironment. The election of a non- 
traditional president in this time of change indicates 
that our specialty, as represented by this Society, is 
willing to earnestly confront he issues that are influ- 
encing the way we currently practice vascular surgery. 
The last four decades have seen profound changes 
in the socioeconomic structure of medicine. Medical 
treatment is now considered a right, not a privilege. 
Demands are being placed on our medical clinicians 
and institutions to increase coverage while decreasing 
the costs for the resultant improved products and 
services. Currently 14% of the U.S. gross national 
product is committed to medical care. In an attempt 
to reduce this figure, managed care organizations 
have emerged as an insurance coverage system that 
significantly alters the way we practice medicine. 
Coalitions of hospitals, companies, and more impor- 
tantly, coalitions of insurance agencies have developed 
into influential and powerful entities. These mega- 
organizations are new and unfamiliar to us, and as a 
specialty we are attempting to formulate a strategy to 
responsively interact with them. Concurrent with all 
these reforms, revisions, and restructuring to our 
environment, we have witnessed revolutionary ad- 
vances in technology. In our specialty advances have 
occurred in the development of techniques, drugs, 
procedures, instruments, and improved services that 
are rapidly replacing our standard, conventional mod- 
els. We are immersed in a technologic revolution in 
which altered socioeconomic forces require us now, 
more than ever, to question: "Who we are, what we 
do, and where we are going." I will give my persl~ec- 
tive on these important questions that face our 
specialty. 
WHO WEARE 
If we respond individually, the answer is obvious 
and straightforward. Each of us is a surgeon who has 
gained additional training and expertise in the diag- 
nosis, treatment, and management of vascular disease. 
When attempting to further define the question as a 
collective, the response becomes much more com- 
plex. Certainly, the response is not uniform. When 
questioning "who we are," the answer is couched in 
terms of what person, or what institutional ffiliation 
serves to characterize us. For those in traditional 
private practice, the name of the hospital or clinic is 
used as an additional identifier. That physicians iden- 
tify themselves with dissimilar descriptions serves to 
document that they not only perceive themselves as 
dissimilar, but in fact, function with very different 
perspectives. Physicians have segregated themselves 
into two camps: academicians and private-practice 
physicians. Despite having a partnership within the 
same specialty, academicians and private practitioners 
have remained quite distinct and separate. The rela- 
tionship between the two camps has historically varied 
from good to bad or indifferent, and in some situa- 
tions, has been downright confrontational. 
The criticism directed at one another over the 
years has been somewhat consistent. It is worth 
reviewing the activities and relationships that have 
been the source of this criticism. Private practitioners 
viewed academicians a  elitist, somewhat rtificial, and 
perceive that they are unrealistic, do not work hard, 
and are therefore conomically deprived. They felt 
this group was more concerned with academic ad- 
vancement than clinical care. Teaching and research 
were used as mechanisms to achieve that end. The 
academician did not address real-world issues, but 
instead created artificial environments protected by 
the socialistic structures that academic institutions 
tend to foster. 4 In this unrealistic environment they 
taught, researched, and practiced medicine while 
failing to recognize how little their efforts influenced 
the real world of medicine. There are, however, some 
good attributes that private practitioners ecognize. 
Academicians are influential, scientific, altruistic, cur- 
rent, and good teachers. 
In turn, the physicians associated with teaching 
and academic enters consider private practitioners 
wealthy or economically advantaged, uninformed, 
late-adopters, non-scientific, and not very influential. 
In addition, academicians have often held the view 
that private practice centers were environments where 
financial return became the most important issue of 
practice. Basic research was never done in these 
environments. Meaningful clinical research was rarely 
done, as this activity was considered time-consuming 
and expensive and did not bring value to the bottom 
line. Even when clinical research was performed, it
was viewed with suspicion by academic centers. Prac- 
titioners were viewed as too busy to contribute to the 
teaching effort. When they did contribute, their value 
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was often considered marginal. On the plus side, 
private practice physicians were considered efficient, 
practical, pragmatic, as possessing technical talent, 
and as being educable. 
The opinions that these two groups have of one 
another when analyzed honestly are unkind, and 
when stated succinctly results in these perspectives. 
The university physician perceives private practitio- 
ners as individuals whose pursuit of money often 
results in bad judgment. The private practitioner 
views the university-based physician as an individual 
who generates useless papers and meaningless titles. 
In fact, there are at times and in some situations, 
elements of truth in the statements made by each. 
Both groups are functioning to fulfill their own 
personal agendas, and each is partially correct in their 
assessment that the others' activities are self-serving. 
Academic advancement i  and of itself is not bad, and 
should be viewed as an admirable goal. When this goal 
becomes so overriding that clinical care, teaching, and 
research become minor objectives, balance is lost. In 
this unbalanced environment, if inappropriate ad- 
vancement occurs, those who follow also become un- 
balanced. The pursuit of wealth in and of itself, like- 
wise, is not bad or evil. An overemphasis on wealth, 
however, can lead to inappropriate and unnecessary 
procedures that result in compromised patient care. 
More recently, unbridled competition on the part of 
both groups for patients has resulted in very destruc- 
tive and inappropriate activity that has further sepa- 
rated these groups from cooperative efforts. 
The question one should ask is; "Do these per- 
ceptions make any difference?" As recently as 10 years 
ago a lack of or a poor relationship among these 
groups in most circumstances had little impact on 
their function. In the current environment, because of 
changing technology and socioeconomic issues, it has 
become crucial to not only relate to one another but 
also to work closely together to benefit our profession 
and the patients we serve. Traditional private practi- 
tioners and those associated with training centers are 
going to have to alter their attitudes, approaches, and 
relationships to one another if they are going to 
continue to enjoy their past successes. This relates to 
the most critical issue facing all physicians, both 
academic and private sectors alike: the ultimate viabil- 
ity of our teaching centers. Universities are dealing 
with a lack of research funding and decreasing finan- 
cial support for postgraduate education. Fiscal effi- 
ciency is required if academic institutions are to 
remain intact as clinical centers. This effort should not 
be the sole responsibility of the academic community 
alone. It should be recognized that fiscally experi- 
cnced private practitioners can have a vital role in this 
endeavor and should be involved in the joint process. 
As well, the Lifeline Foundation, as the research arm 
of the Society for Vascular Surgery and the Interna- 
tional Society for Cardiovascular Surgery, North 
American Chapter, has been chartered to address the 
key issues of research and the education of young 
specialists in vascular surgcry. We are obligated to 
support its efforts. If these actions are not initiated, 
our educational institutions will continuc to be com- 
promised or function at a low level, and the future of 
American medicine will be jeopardized. 
WHAT WE DO 
"What we do" may be answered simply: we are sur- 
geons who operate on the vascular system, and we have 
been taught o do this by cutting and sewing. The 
university's traditional role is to provide direction, de- 
velop new procedures, and advance technology, and 
then to educate and promulgate this information to 
students, trainees, and those in active practice. To ac- 
complish this goal totally independent of the private 
practitioner is difficult in some situations and is virtu- 
ally impossible under certain circumstances. 
For example, many common general surgical 
procedures such as hernia repair and cholecystectomy 
are infrequently performed inmany academic centers. 
Academic surgeons arc unlikely to develop improve- 
ments related to procedures that they rarely perform. 
In fact, less-invasive general surgery was initiated and 
developed primarily by private-practice physicians, '6 
In the field of vascular surgery, as previously alluded 
to, a close relationship between the academic om- 
munity and private practitioners i  also lacking. The 
following statistics will serve to make this point. Of all 
major vascular procedures performed in the United 
States in 1994, between 10% and 12% were carried out 
in the university setting. Private institutions provided 
the setting for approximately 88% of these major 
vascular procedures. A review of the official Journal of 
our Society for the year 1994 revealed that 85% of the 
scientific articles that were published originated in 
university environments, whereas only 15% of them 
came from private institutions. To say that this is an 
imbalance is an understatement. Contributing uni- 
versity groups are reporting on a small and highly 
select segment of patients. The largest portion of 
clinical material is not being reported on and is very 
likely not being analyzed. The criticism is obvious. 
Private practitioners are not contributing to the 
extent hey could be and should be. The academic 
community is reporting too much on too little. Our 
specialty would be better served if the literature 
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Fig. 1. Shift in relative balance ofinfluence on patient care. 
reflected a cooperative and balanced case selection 
offered by both groups. This requirement becomes 
critically important when one considers that managed 
care organizations will mandate outcome data on the 
procedures we p rform. It is no longer sufficient o 
provide the self-proclaimed best care concept that 
previously served to satisfy the patient, the patient's 
family, and the referring physician. Contracts for 
patient care will be awarded on the basis of cost, 
outcome analysis, and the ability to negotiate. Out- 
come analysis can only be understood when the entire 
spectrum of disease is considered. Private practitio- 
ners, in general, deal with less-complex clinical cases. 
Academic centers traditionally treat more advanced 
diseases and manage patient groups that present 
significant echnical challenges. Because of this selec- 
tion process, the reported literature can often indicate 
higher mortality and morbidity rates than actually 
exist. If one were to look at outcome analysis with this 
biased view of case selection, what is reported will not 
be representative of our specialty's efforts. We must 
become more cohesive in assessing and reporting 
what we do in a uniform fashion. 
Additional factors should serve to unify us. Pow- 
erfifl unifiers are the threats common to both pri- 
vate practitioners and academicians. These common 
threats are a decrease in influence, a decrease in 
independence, an increase in competition from other 
specialists, a decrease in financial resources, and the 
emergence of the general practitioner as gatekeeper. 
If wc observe the shift in the balance of influence 
exerted by physicians on the therapeutic decision to- 
day contrasted to I960, we would find a most inter- 
esting and disheartening occurrence. Fig. 1 graphi- 
cally illustrates this shift. In 1960 physicians made 
therapeutic decisions in consultation with the patient, 
the patient's family, and the referring physician. In 
1995 we are dealing with a totally different decision 
model. Today players involved in influencing thera- 
peutic decisions are the treating physician, the refer- 
ring physician, insurance companies, government and 
regulatory agencies, industry, and hospital adminis- 
tration and staff. The balance has dramatically shifted. 
Physician input and influence has precipitously de- 
clined, and in its place we see a significant increase in 
the influence exerted by regulatory agencies and in- 
surance companies in determining what we can do 
and how we may do it. This situation should not exist. 
A simple but important concept is founded in the 
principle that the therapeutic decision should ulti- 
mately be made at the highest level of knowledge and 
integrity. Those best qualified to make these decisions 
are physicians in the practice of medicine, caring for 
the individual patient. 
I would like to address the increasing and poten- 
tially adverse influence of government regulatory 
agencies. Two governmental gencies that have im- 
pacted us most profoundly are the Food and Drug 
Administration (FDA) and the Health Care Finance 
Administration (HCFA). Although there is insuffi- 
cient time to address in detail the heavy influence of 
both organizations, I want to briefly mention how 
each impacts us in our daily practice of medicine. 
By law, the FDA has the responsibility of address- 
ing safety and efficacy issues associated with the use of 
drugs and devices. This process is implemented and 
directed through guidelines and regulations devel- 
oped by the agency. Proposed clinical protocols for 
investigational drugs and devices are submitted to the 
agency for review and approval. After protocol ap- 
provals and completion of studies, FDA panels either 
approve or disapprove submissions. It is obvious that 
the functioning of this regulatory process can signifi- 
cantly influence the availability of drugs and devices 
and the manner in which they are used. Inappropriate 
delays in the regulatory process can result in multiple 
adverse situations. Improved treatments are denied to 
patients and developmental costs are significantly 
increased when the approval process is lengthy. Re- 
gardless of the length of time that a properly struc- 
tured study takes to coml~lete , adverse effects are 
sometimes identified in small groups of patients. A 
common response of regulatory agencies when pre- 
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sented with this conflict is to delay decisions or to do 
nothing. They seek to avoid any possibility of adverse 
effects by these indecisive actions and instead add 
additional documentation requirements, which only 
serve to further lengthen the approval processing 
time. A simple retreat o erring on the side of safety 
has the potential of further harming the economic and 
health accruing benefits that may be garnered by 
applying new technology to medicine. It is important 
to recognize other areas that the FDA also influences. 
Three additional vital areas in need of reform are (1) 
the availability of biomaterials, (2) "off-label" use of 
drugs and devices, and (3) reimbursement for in- 
vestigational devices. Recent internal government 
criticism directed toward "the agency" (FDA) and 
mounting pressure from the drug and device in- 
dustry have resulted in some very positive changes. 
The FDA has recently recruited increasing numbers 
of physicians who have clinical practice backgrounds 
and placed them in responsible positions where they 
advise regarding the nature and structure of clinical 
trials. Dr. Kessler has undertaken a departmental 
reorganization aimed at eliminating delays in the 
approval process for new drugs and devices. Aban- 
doning the concept of applying drug study models 
to device study design has resulted in more appro- 
priate device evaluations and subsequent decreased 
approval times. 
The HCFA, under the auspices of the Department 
of Health and Human Services, is responsible for 
administering federally funded medical insurance 
programs. In May 1994 this agency subpoenaed over 
100 hospitals for patient billing and hospital records. 
The subpoena was requested for the purpose of 
documenting those patients who had devices used or 
implanted that were under FDA clinical trial auspices. 
The agency's implication was that these procedures 
should not have been reimbursed for either the 
professional or institutional components. All docu- 
ments dating back to 1984 were requested. Institu- 
tional responses varied. Some refused to cooperate, 
whereas others formed coalitions of hospitals and filed 
suit against he agency for this action. Many institu- 
tions initiated internal audits in an attempt to satisfy 
the subpoena. A more dramatic response chosen by 
several major academic centers was to terminate 
clinical trials in progress and suspend consideration of
any new studies. I consider this latter action gutless, 
totally inappropriate, contrary to the academic mis- 
sion, and adverse to efforts eeking to improve patient 
care. Fortunately, inthe interim it appears that HCFA 
has abandoned this investigation. The real question 
generated by this activity relates to a socioeconomic 
issue: "Who should pay for investigational devices and 
drugs?" The answers depend on several premises and 
determinations, but all relate to who receives value 
from the new drug or device and who provides that 
value. There are numerous potential givers and recipi- 
ents of"value." They are patients, hospitals, insurers, 
manufacturers, and physicians. Historically each of 
these value-givers and recipients have mutually ben- 
efited through technologic advancement, and they 
should continue to be allowed to do so without 
government intrusion. In this environment where 
government influence is becoming more dominant, 
physicians have additional obligations. As treating 
practitioners, we should work to effect attitudinal and 
legislative changes that would enable the regulatory 
process to become more user-friendly and efficient. If 
the above issues go unresolved, our patients will not 
receive the best and most current reatment, and the 
United States health care industry will continue to 
relocate offshore for both manufacturing and clinical 
investigation. 
WHERE WE ARE GOING 
Where we as a specialty will go will be determined 
by how we respond to current changes. Socioeco- 
nomic changes require us now, more than ever, to 
include economics in our decision-making process 
when considering a therapeutic approach. We will be 
required to choose a therapy based both on clinical 
and cost effectiveness, regardless of our training, 
background, or clinical perspectives. In particular, 
emerging endovascular technologies will displace 
some procedures traditionally managed by our stan- 
dard surgical approach. In light of this change, it is 
interesting and timely that less-invasive technologies 
offer the possibility of reducing overall cost while still 
optimizing clinical benefits. The unanswered ques- 
tions that remain are: "How much and how soon?" 
Fig. 2 represents my perspective on the current 
status and future anticipated use of endovascular 
alternatives used to treat vascular disease. If these 
forecasts prove to be accurate on the basis of even the 
lowest projected numbers, vascular surgeons have 
limited options: adopt he new technology, reject he 
technology and do what is left, retire, or learn another 
profession. Depending on one's focus, commitment, 
and stage in life, any of the above options may be 
viable for a given individual. As a specialty that serves 
the interest of our patients, however, it is my recom- 
mendation that we become integrally involved in the 
appropriate volution of endovascular technology. 
We should adopt what is useful and abandon what is 
not. If existing technology is abandoned it will be 
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Fig. 2. Intrusion of endovascular surgery on standard surgery. 
done because it is inferior to the new technology. 
When we accept this fundamental concept, barriers to 
future technologic advances will fall. The manner in 
which practicing physicians become a part of this 
process may differ depending on the environment. In
some situations, a close collaborative relationship 
with a radiologist or cardiologist may prove to be the 
most viable approach. I f  these cooperative relation- 
ships are not accessible or workable, the surgeon may 
find it necessary to pursue endovascular technology 
independently. I f  this solo direction is chosen, it 
should be followed with a firm commitment todevote 
the time, focus, and energy required to obtain the 
skills necessary to master these techniques. 
The academic community has an obligation in this 
process. The traditional teaching centers have spent 
much of their training time emphasizing the number 
of techniques and procedures done by their gradu- 
ates. Although this is important, too little time has 
been allotted to the process of critical thinking and 
judgmel~t. The dedication to structure, discipline, 
and consistent repetitive behavior that has made us 
proficient may prove to be our Achilles' heel. Many of 
us have become so structured that we have failed to 
recognize the potential of competing technologies. 
The time has come for the academic institutions to 
question some of their basic premises. It is quite 
possible that they are not the only source of all 
knowledge. 
A broader and more global perspective on changes 
in specialty training should be considered by univer- 
sity programs. It is my belief that the traditional 
departmental structures have outlived their uscful- 
hess. They must either adapt to accommodate new 
ideas or bc replaced with contemporary s stems. It is 
important to recognize that current echnology has 
allowed us to diagnose and treat in many ways that do 
not involve the use of our traditional surgical 
approaches: cutting and sewing under direct vision. 
Evaluation and adoption of endovascular technology 
is best accomplished in an environment that is in 
evolution. Because multiple specialists each possess 
individual talents involved in the treatment process, 
university centers should develop groups to effec- 
tively manage disease, regardless of their specialty 
training. This will involve breaking down and crossing 
traditional departmental boundaries. It is my firm 
opinion that ftmctionally and fiscally integrated 
groups that consist of vascular surgeons, interven- 
tional radiologists, cardiologists, and cardiac surgeons 
will best administer care to patients with cardiovascu- 
lar disease. The concept of a team management 
approach for treating disease will put individuals from 
different specialties together to address all aspects of 
the disease ntities we treat. To be successful with this 
modern treatment model, we must minimize the large 
fiscal differentials that now exist between the different 
specialties, particularly if they are all operating within 
the same group. In addition, we must aggressively 
deal with the issues of managed care. As physicians, we 
will be obligated to concern ourselves with contrac- 
tual arrangements, for if we do not, we will not have 
access to the diseases we have historically treated. 
Consequently, we will not become skillful with the 
appropriate uses of new technology and services. 
Vascular surgeons know more about the pathology, 
pathophysiology, natural history, and care of patients 
with vascular disease than any other physician group. 
It must follow then that if we are going to form 
multispecialty associations, it is appropriate that we 
maintain a dominant position within that organiza- 
tion. If the lion and the lamb are going to lie together, 
it is best to be the lion. Several universities and private 
practice groups have already embraced this concept 
and have constructed multispecialty vascular centers 
under the direction of vascular surgical specialists. It is 
my belief that only those who implement this ap- 
proach will become the superior training centers and 
maintain their fiscal viability. 
Although there appears to be significant uncer- 
tainty and unrest in the medical world, it is my 
contention that the future is optimistic. As physicians 
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attempting to influence the future, it is important to 
accept hat we may not be adequately prepared in all 
areas. In the past physicians have achieved success by 
effectively practicing the familiar art and science of 
our profession. We must now also exert our influence 
on the social, economic, governmental, educational, 
and political issues that are currently impacting the 
way we care for our patients. It is well to remember 
that patients, as consumers, will be the arbitrators and 
final determinants of the future character of medical 
care. Physicians, however, as the only individuals who 
are the personal and "hands-on" interface with pa- 
tients, have the ultimate ability to influence their 
perspective. Whether we choose to exercise that 
influence depends on our ability to effectively com- 
municate that we, as caring physicians, are acting in 
the patients' best interests. Activities and expressions 
that relay a contrary message must be avoided. 
In this time of turbulence and change, it is never 
more true that knowledge and wisdom are power. I
believe that the Society for Vascular Surgery, along 
with our brother and sister societies, do possess that 
knowledge, wisdom, and power. I am quite confident 
that we as a specialty are going to do well if we choose 
to follow a constructive direction of dynamic hange. 
The future is bright, the path is clear, and the 
responsibility is ours. 
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